Transgenic Overexpression of Galectin-3 in Pancreatic β Cells Attenuates Hyperglycemia in Mice: Synergistic Antidiabetic Effect With Exogenous IL-33.
2021
Аутори:
Jovičić, NemanjaPetrović, Ivica
Pejnović, Nada
Ljujić, Biljana
Miletić Kovačević, Marina
Pavlović, Slađana
Jeftić, Ilija
Đukić, Aleksandar
Srejović, Ivan
Selaković, Dragica
Jakovljević, Vladimir
Lukić, Miodrag L.
Остала ауторства
Selaković, DragicaТип документа:
Конференцијски прилог (Објављена верзија)
,
© 2021 The Authors. European Journal of Immunology published by Wiley-VCH GmbH
Метаподаци
Приказ свих података о документуАпстракт:
Galectin 3 (gal 3) has diverse roles in inflammatory and autoimmune diseases. There is evidence that galectin 3 plays a role in both, type 1 and type 2 diabetes. While the role of Gal‐3 expression in immune cells in experimental type 1 diabetes has been already studied, the importance of the overexpression of Gal‐3 in the target β cells is not defined. We used 10‐12 weeks old C57/BL6 male mice (WT) and C57/BL6 mice with transgenically enhanced Gal‐3 expression in pancreatic β cells (TG). Both groups, received STZ for 5 consecutive days at a dose of 40 mg/kg ip. Mice received exogenous mouse IL‐33 (0.4 μg/injection) i.p., 12th, 14 th, 16 th, and 18 th day after the disease induction. Control animals were treated with intraperitoneally PBS + citrate buffer or IL‐33 + citrate buffer. The overexpression of Gal‐3 protected β cells from apoptosis and attenuated MLD‐STZ induced hyperglycemia, glycosuria and ketonuria. The cellular analysis of pancreata and draining lymph nodes showed that Gal‐ 3 overexpression significantly decreased the number of proinflammatory cells without affecting T regulatory cells. The application of exogenous IL‐33, attenuates the development of disease, by increasing the presence of regulatory FoxP3+ ST2+ cells, and competely abrogate diabetogenesis. We demonstrated the potential synergistic effect of exogenous IL‐33 and TG overexpression of Gal‐3 in β cells Not only enhanced expresion of Gal‐3 in β cells reduced T cell mediated autoimmune inflammatory disease, but also exogenous IL‐33 application had powerful terapeutic effect in TG mice.
Кључне речи:
Animal models; autoimmunity; cytokines and mediators; diabetesdrugs for immune modulationУ:
- Abstracts of ECI 2021: 6th European Congress of Immunology; 2021 Sep 1-4; Virtual Meeting. John Wiley and Sons; 2021. p. 378. (European Journal of Immunology; Vol. 51; No. S1).
URI
https://onlinelibrary.wiley.com/toc/15214141/2021/51/S1http://radar.ibiss.bg.ac.rs/handle/123456789/4880